Added to YB: 2026-09-15
Pitch date: 2026-09-12
BIOA [neutral]
BioAge Labs, Inc.
-0.47%
current return
Author Info
No bio for this author
Company Info
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
Market Cap
$389.7M
Pitch Price
$8.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.11
P/E
-3.58
EV/Sales
1.09
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage day 4 session 3 - BioAge Labs, Inc.
BIOA (update): BioAge’s strategic appeal rests on cross-indication optionality for oral NLRP3 inhibitor BGE-102, led by a pivotal-path DME opportunity, plus an APJ/apelin muscle-preservation franchise. Phase 1 showed up to 98% IL-1β suppression and an 86% CRP reduction; QUILT-CV offers year-end pharmacology validation, but the decisive readout is DME visual acuity in 2H27. The principal risk is that strong biomarkers fail to translate into clinical benefit.
Read full article (3 min)